[Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
In this study we examined a combined immunotherapy using lymphokine activated tumor infiltrating lymphocytes and active specific immunotherapy with virus-modified tumor cells in disseminated breast and ovarian cancer patients. During the therapy a significant increase in cytotoxicity could be observed, which nevertheless could not be maintained after the end of therapy. In an ongoing prospective randomized study we are using antigen specific stimulated cytotoxic T-lymphocytes to extend this effect.
Mallmann
P
P
Universitäts-Frauenklinik Bonn.
Krebs
D
D
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000637:transplantation*; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000637:transplantation*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
Gewinnung und Aktivierung tumorinfiltrierender Lymphozyten (TIL) im Rahmen einer Lymphokinaktivierten Killerzelltherapie (LAK-TIL-Therapie) bei Patientinnen mit fortgeschrittenen Mamma- und Ovarialkarzinom.